230 related articles for article (PubMed ID: 10897051)
1. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
3. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
4. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
Tigli H; Yazici H; Dalay N
Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
6. No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk.
dos Santos A; Ribeiro ML; Mesquita JC; Carvalho-Salles AB; Hackel C
Prostate Cancer Prostatic Dis; 2002; 5(1):28-31. PubMed ID: 15195127
[TBL] [Abstract][Full Text] [Related]
7. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
8. A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss.
Sata F; Yamada H; Yamada A; Kato EH; Kataoka S; Saijo Y; Kondo T; Tamaki J; Minakami H; Kishi R
Mol Hum Reprod; 2003 Nov; 9(11):725-8. PubMed ID: 14561815
[TBL] [Abstract][Full Text] [Related]
9. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism in the CYP17 gene and risk of prostate cancer.
Stanford JL; Noonan EA; Iwasaki L; Kolb S; Chadwick RB; Feng Z; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):243-7. PubMed ID: 11895872
[TBL] [Abstract][Full Text] [Related]
11. CYP17 gene polymorphism and its association in north Indian prostate cancer patients.
Sobti RC; Gupta L; Thakur H; Seth A; Singh SK; Kaur P
Anticancer Res; 2009 May; 29(5):1659-63. PubMed ID: 19443382
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer associated with CYP17 genotype.
Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E
Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544
[TBL] [Abstract][Full Text] [Related]
14. [Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men].
Guli MR; Wang JQ; Zhang JX; Deng G
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):120-2. PubMed ID: 16519145
[TBL] [Abstract][Full Text] [Related]
15. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between CYP17 Mspa1 polymorphism and prostate cancer risk: a meta-analysis of 14494 cases and 15971 controls.
Song G; Gu L; Tian F; Bao Q; Tang Z; Wang S
Medicina (Kaunas); 2013; 49(2):51-5. PubMed ID: 23888338
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism in the Androgen Biosynthesis Gene (CYP17), a Risk for Prostate Cancer: A Meta-Analysis.
Effah CY; Wang L; Agboyibor C; Drokow EK; Yu S; Wang W; Wu Y
Am J Mens Health; 2020; 14(5):1557988320959984. PubMed ID: 32964792
[TBL] [Abstract][Full Text] [Related]
18. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer.
Chang B; Zheng SL; Isaacs SD; Wiley KE; Carpten JD; Hawkins GA; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB; Xu J
Int J Cancer; 2001 Nov; 95(6):354-9. PubMed ID: 11668516
[TBL] [Abstract][Full Text] [Related]
19. CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population.
Souiden Y; Mahdouani M; Chaieb K; Elkamel R; Mahdouani K
Cancer Epidemiol; 2011 Oct; 35(5):480-4. PubMed ID: 21193363
[TBL] [Abstract][Full Text] [Related]
20. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
